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Thyroid hormones are iodothyronines that control growth and development, as well as brain function and me-
tabolism. Although thyroid hormone deﬁciency can be caused by defects of hormone synthesis and action, it has
not been linked to a defect in cellular hormone transport. In fact, the physiological role of the several classes of
membrane transporters remains unknown. We now report, for the ﬁrst time, mutations in the monocarboxylate
transporter 8 (MCT8) gene, located on the X chromosome, that encodes a 613–amino acid protein with 12 predicted
transmembrane domains. The propositi of two unrelated families are males with abnormal relative concentrations
of three circulating iodothyronines, as well as neurological abnormalities, including global developmental delay,
central hypotonia, spastic quadriplegia, dystonic movements, rotary nystagmus, and impaired gaze and hearing.
Heterozygous females had a milder thyroid phenotype and no neurological defects. These ﬁndings establish the
physiological importance of MCT8 as a thyroid hormone transporter.
Thyroid hormone plays a major role in vertebrate
growth and development. It is absolutely necessary for
amphibian metamorphosis and in mammals for brain
development and metabolism. Its deﬁciency causes se-
vere brain malfunction that, if not treated in early post-
natal life, causes irreversible cretinism in humans. This
is in part due to hypomyelination and to defects of cell
migration and differentiation (Bernal 2002).
The crucial role of thyroid hormone in fetal and early
postnatal development has been established not only in
animals but also in humans. The serious consequences
ensuing from maternal hypothyroidism and early child-
hood hormone deprivation have been documented in
endemic areas of iodine deﬁciency (Delange 2000) and
in inherited and acquired hypothyroidism occurringwith
high frequency in the Western world (Morreale de Es-
cobar et al. 2000).
Thyroid hormones are iodothyronines synthesized in
the thyroid gland. Their constant supply is ensured by
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two mechanisms: (1) secretion of hormone controlled by
a feedback system involving the hypothalamo-pituitary-
thyroid axis (Morley 1981) and (2) hormone activation
within the cells regulated by tissue iodothyronine deio-
dinases (St. Germain and Galton 1997). Thyroid-stim-
ulating hormone (TSH), originating from thyrotrophs in
the pituitary gland, promotes the synthesis and secretion
of thyroid hormones, principally 3,5,3′,5′-tetraiodothy-
ronine (T4), or thyroxine. T4 is considered to be a pro-
hormone, since it is converted to a biologically more
potent hormone, 3,3′,5-triiodothyronine (T3), by 5
′-
monodeiodination in virtually all tissues. In contrast,
removal of an iodine from the 5 position produces the
inactive metabolite 3,3′,5′-triiodothyronine, or reverse T3
(rT3). T3, but not rT3, suppresses TSH secretion, closing
the tightly regulated feedback loop (Larsen et al. 1981).
The effects of thyroid hormone are dependent on the
quantity of the hormone that reaches peripheral tissues
and the availability of unaltered thyroid hormone re-
ceptors in cell nuclei. There is an excellent correlation
between serum free T4 and T3 concentrations and the
activity level of thyroid hormone–dependent processes.
This apparent equilibrium between the intracellular and
serum free fraction of the hormone has perpetuated the
hypothesis of passive thyroid hormone diffusion into
target cells (Ekins 1992). Nevertheless, several classes of
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membrane transporters with different kinetics and sub-
strate preferences have been identiﬁed as likely candi-
dates for transmembrane thyroid hormone carriers
(Hennemann et al. 2001; Abe et al. 2002; Friesema et
al. 2003). Their physiological role, however, remains un-
known. This is principally because, in contrast to the
common defects of thyroid hormone synthesis and ac-
tion, no defects of membrane transport proteins have
been identiﬁed so far (Refetoff et al. 2001).
In this paper, we report two families with unusual
thyroid function tests showing abnormalities in the rel-
ative serum levels of iodothyronines, measured by spe-
ciﬁc immunometric assays (Elecsys 2010 [Roche]). The
studies were approved by the institutional review board
of the University of Chicago.
Family Ro is of German origin. The propositus, an 8-
year-old boy, is the second child born to nonconsan-
guineous and apparently healthy parents, after an un-
eventful pregnancy and delivery. Neonatal screening for
congenital hypothyroidism showed normal TSH levels
but neurological defects were apparent during the 1st
wk of life. Thyroid function tests obtained at 5 mo of
age were allegedly normal (values not available). Ab-
normal thyroid tests, ﬁrst observed at 17 mo of age,
consisted of low total T4 (TT4) of 3.3 mg/dl (normal range
4.5–13 mg/dl) and borderline high TSH of 4.1 mU/L
(normal !4 mU/L), which became overtly elevated (8.6
mU/L) at 24 mo, prompting treatment with 50 mg/day
of L-T4. Neurological abnormalities in the 1st wk con-
sisted of dystonia, irritability, feeding problems, and ro-
tary nystagmus. Subsequent motor and mental devel-
opment was severely delayed. At the age of 2 years, the
boy was unable to sit, crawl, or stand and had parox-
ysmal dystonia. No seizures were observed, and electro-
encephalogram (EEG) results and magnetic resonance
imaging (MRI) were normal. No further progress oc-
curred over the ensuing 5 years. There was no verbal
communication or gaze contact, and the child was quad-
riplegic. He was macrosomic at birth and during the 1st
year of life, but height and weight were in the 50th
percentile from the 2nd year on, and bone age was nor-
mal. The onset of insulin-dependent diabetes mellitus,
at 3 years of age, was heralded by an episode of hyper-
osmolar coma with moderate ketoacidosis. There is no
family history of neurological diseases, and an older
brother is healthy. The most recent thyroid function tests
revealed low TT4, free T4 index (FT4I), and rT3, with
high TT3 and slightly elevated TSH (ﬁg. 1A). These re-
sults were replicated in several samples collected at dif-
ferent times. Free T4 (FT4) was also low, at 0.67 ng/dl
(normal range 0.77–1.53 ng/dl), and free T3 was high,
at 5.2 pg/ml (normal range 2.3–4.2 pg/ml). The mother
of the propositus showed a milder form of the pheno-
type, with low or low-normal TT4, FT4I, and rT3, normal
TSH, and high-normal TT3, and with no neurological
abnormalities. Other family members did not exhibit the
same thyroid phenotype (ﬁg. 1A). A maternal aunt, an
uncle, and the grandmother have autoimmune thyroid
disease (AITD), as evidenced by positive peroxidase and
thyroglobulin antibodies. The isolated thyroid function
test abnormalities in these subjects are related to AITD.
Family Fi is of a combined ethnic background, in-
cluding Scottish, English, and Cree Indian. The 3-year-
old male propositus was the product of a full-term preg-
nancy and normal delivery. Neonatal screening showed
a low T4 and normal TSH. These results were conﬁrmed
at the 12th postnatal day, showing a T4 of 4.7 mg/dl
(normal 17 mg/dl) and a TSH of 1.5 mU/L. Additional
tests showed low FT4 but otherwise a vigorous infant
and no stigmata of congenital hypothyroidism. The
working diagnosis was central hypothyroidism, and the
infant was started on 37.5 mg/day of L-T4. At 3 mo of
age, he was having feeding problems, with recurrent as-
piration, frequent emesis, intermittent dysconjugate eye
movements, and central hypotonia, followed by in-
creased peripheral hypertonia, resulting in spastic quad-
riplegia. MRI of the brain was normal. Thyroid function
tests at 17 d, 6 mo, and 8 mo showed the same pattern
as that observed at 2 years of age (ﬁg. 2A), as well as
that of the propositus from family Ro—namely, low TT4
and FT4, with high TT3, FT3, and TSH, while on a low
dose of L-T4. The mother of the propositus, a maternal
aunt, and the maternal grandmother showed a milder
thyroid phenotype, with borderline low TT4, FT4I, and
rT3 but normal TT3 and TSH (ﬁg. 2A). The maternal
aunt was severely handicapped by mental retardation
but had no other neurological abnormalities. One ﬁnd-
ing of interest was that a maternal uncle with cerebral
palsy, severe global developmental delay, and seizure dis-
order, died at 10 years of age. The postmortem diagnosis
was Reye syndrome, showing cerebral edema, fatty-liver
changes, and serum varicella antibodies. At the time of
the autopsy, a general atrophy of the skeletal muscles
was noted—in particular, the muscles of lower limbs—
and the toes were ﬂexed. Other ﬁndings were loss of
neurons in the cerebral cortex, cerebellum, and basal
ganglia. The latter also had small deposits of calcium.
The maternal grandfather had a mild TSH elevation due
to AITD, which was conﬁrmed by positive peroxidase
antibodies.
The reciprocal elevation of serum T3 concentration
relative to that of rT3 suggested the possibility of a defect
in thyroid hormone metabolism. Accordingly, we ﬁrst
searched for linkage of the thyroid phenotype to the
three iodothyronine deiodinases located on chromo-
somes 1 and 14 (Bianco et al. 2002). Using informative
polymorphic markers to genotype the families, we were
able to exclude linkage to all three genes (not shown).
We therefore turned to the newly characterized io-
dothyronine transporter, MCT8 (Friesema et al. 2003).
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Figure 1 Family Ro. A, Pedigree and thyroid function tests. Values above the upper limit of normal are shown in red, and those below
the lower limit of normal are in blue. TT4p total T4; TT3p total T3; TrT3p total reverse T3; FT4Ip free T4 index; TSHp thyroid stimulating
hormone; AITDp autoimmune thyroid disease; MCT8p monocarboxylate transporter 8. B, Electropherograms showing the mutation found
in exon 5 of MCT8 in the propositus (top tracing) and the corresponding normal sequence (bottom tracing). C, Results of genotyping of all
family members for the mutation shown in B. A 530-bp fragment, ampliﬁed by PCR and containing sequences of the WT exon 5, produces
two bands, 327 bp and 203 bp, when digested with HpaII. The mutant allele has a new HpaII restriction site producing two additional bands,
235 bp and 92 bp (latter band not shown), by further digestion of the 327-bp fragment. This occurs in the hemizygous propositus and the
heterozygous mother. D, The inheritance pattern of the MCT8 locus on chromosome X, investigated using polymorphic markers in the vicinity
of MCT8. Three alleles are identiﬁed in the grandparents of the propositus. The affected allele transmitted from the mother is shown in red.
The location of this gene on the X chromosome and the
more severe expression of the phenotype in the males of
these two families, with the females only mildly affected,
made MCT8 a likely candidate gene. Indeed, in both
families, males had more pronounced thyroid hormone
abnormalities, as well as a neurological phenotype. The
four females had a milder thyroid phenotype, and none
exhibited the neurological defects present in the males
(ﬁg. 3). Thus, we sequenced (ABI 377 [PerkinElmer]) all
ﬁve exons and ﬂanking intronic sequences of the MCT8
gene by use of genomic DNA obtained from circulating
mononuclear cells. Single-nucleotide mutations were
identiﬁed in affected subjects of both families.
In family Ro, a T-to-C transition in codon 512 in exon
5 (c.1535TrC) predicts the replacement of the normal
leucine (CTG)with a proline (CCG),mutation L512P (ﬁg.
1B). This mutation is located in the ﬁfth intracytoplasmic
loop of MCT8, at the junction with the 10th transmem-
brane segment. The mutation creates a new HpaII re-
striction site, which was used to genotype all members
of the family. As shown in ﬁgure 1C, the 530-bp DNA
generated by PCR ampliﬁcation of the WT exon 5 pro-
duced two bands, 327 bp and 203 bp, when digested
with HpaII (New England Biolabs). In contrast, DNA
ampliﬁed from the mutant allele and digested with the
same enzyme produced two additional bands, 235 bp
and 92 bp, by restriction of the 327-bp fragment. The
propositus was hemizygous and the mother heterozy-
gous for the mutations. No other family members har-
bored this mutation. The pattern of inheritance was fur-
ther examined using the polymorphic tetranucleotide
repeats DXS6800 and DXS6785, located 0 cM and 4.8
cM centromeric from MCT8, respectively. Following
PCR ampliﬁcation, using ﬂuorescent labeled primers
(Research Genetics, Invitrogen), we determined that the
mutant maternal allele was inherited from the unaffected
grandfather (ﬁg. 1D). However, neither he nor his two
unaffected daughters (individuals II4 and II5 in ﬁg. 1A)
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Figure 2 Family Fi. A, Pedigree and thyroid function tests. For details and abbreviations, see the legend to ﬁgure 1. B, Electropherograms
showing the WT reverse sequence from part of exon 3 of the MCT8 gene (upper tracing), the location of the nucleotide deletion in the propositus
(middle tracing), and the sequence of the heterozygous mother (lower tracing). C, Results of genotyping of all family members for the mutation
shown in B. The 178-bp product ampliﬁed from the mutant allele is digested into two fragments of 101 bp and 77 bp by HhaI, whereas the
WT allele remains intact. Complete digestion is observed in the two hemizygous affected males (II4 and III1). The heterozygous females (I2,
II2, and II3) show three bands: the 179-bp fragment representing the WT allele and the two smaller fragments representing the digested mutant
allele.
harbored the L512P mutation, indicating that the mu-
tation occurred de novo in the germline of the grand-
father or early in the embryonic development of the
mother of the propositus.
Sequencing of the MCT8 gene of the affected pro-
positus of family Fi revealed a single-nucleotide deletion
(c.1212delT) in exon 3. The loss of a T in codon 404
(GCT) creates a frameshift starting at the seventh trans-
membrane segment and predicting a nonsense protein
with a stop codon in position 416, at the junction with
the fourth extracellular loop (ﬁg. 2B). This mutation
generates a new restriction site forHhaI. A 178-bp prod-
uct, ampliﬁed from the mutant allele, produces two frag-
ments of 101 bp and 77 bp when digested with HhaI,
whereas the wild-type (WT) fragment remains intact.
Genotyping using this new HhaI site identiﬁed the mu-
tation in one allele of the mother, a maternal aunt, and
the maternal grandmother (ﬁg. 2C). All three also ex-
pressed the thyroid phenotype, although to a lesser ex-
tent than the hemizygous propositus (ﬁg. 2A). We were
able to obtain postmortem material from the maternal
uncle (II4), who died in 1992 at the age of 10 (see above).
Genomic DNA, extracted from parafﬁn-embedded liver
by use of a standard technique (Shi et al. 2002), revealed
that he was hemizygous for the mutation found in the
propositus (III1). Neither of the nucleotide abnormalities
identiﬁed in the two families was present in 218 chro-
mosomes from unrelated normal subjects.
Recently, several thyroid hormone transporters have
been identiﬁed, belonging to different families of solute
carriers, including organic anion, amino acid, andmono-
carboxylate transporters. Eight organic anion trans-
porting polypeptides (OATP) belonging to the solute car-
rier family 21 (SLC21) have been identiﬁed in humans.
They transport different ligands in a sodium-indepen-
dent manner (Abe et al. 2002) and seem to have 12
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Figure 3 Graphic representation of thyroid function tests in the members of the two families. The gray interval denotes the normal range
for each determination. Note that values of affected hemizygous males are outside the normal range for all tests, whereas those of heterozygous
females are, in general, intermediate to the unaffected subjects and affected hemizygotes.
transmembrane domains (TMDs) but low amino acid
identity. Some have been proven to transport thyroid
hormone with different afﬁnities and have variable
translational efﬁciency (Pizzagalli et al. 2002). NTCP
(SLC10A1), expressed only in hepatocytes, has seven
transmembrane domains and transports thyroid hor-
mone but is believed to be the major transporter for
unconjugated bile acids (Hagenbuch andDawson 2003).
The 4F2-related heterodimeric amino acid transporters
belong to the SLC7 family. The ubiquitously expressed
4F2 has one TMD and is linked through a disulﬁte bond
to the L amino acid transporters LAT1 and LAT2, which
have 12 TMDs. In addition to transporting neutral
amino acids in a sodium-independent manner, they also
transport thyroid hormone (Chairoungdua et al. 2001).
Finally, 14 monocarboxylate transporters (MCTs), also
known as “family SLC16,” have been identiﬁed in hu-
mans, but little is known about their function (Halestrap
and Meredith 2003). Four (MCT1–MCT4) have been
demonstrated to catalyze the proton-linked transport of
metabolically important monocarboxylates such as lac-
tate, pyruvate, and ketone bodies (Bonen 2001;Mac and
Nalecz 2003). MCT10 (TAT1) transports amino acids,
and the rat homologue of human MCT8 was found to
be a speciﬁc thyroid hormone transporter (Friesema et
al. 2003).
The wide range of endogenous and xenobiotic mol-
ecules for most of these transporters hampers the pre-
diction of the putative phenotype in transporter deﬁ-
ciency. Their wide distribution and the role played by
their ligands would predict multiple organ involvement.
The ability to transport different iodothyronines sug-
gests an overlapping, redundant function. On the other
hand, their characteristics in terms of different tissue
distribution and kinetics, as well as the binding of other
possible ligands, qualify them to play distinctive roles in
the ﬁne tuning of the organ-speciﬁc availability of thy-
roid hormones. The study of families with abnormalities
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Figure 4 X-inactivation assay using a polymorphic repeat in the AR gene. Gels are aligned with the corresponding members on the
pedigrees. For each individual lane, a dash represents the PCR product of mock digested gDNA (no enzyme added), and “H” denotes the PCR
product using the HhaI-digested gDNA as the template. As expected, no product is obtained using HhaI-digested gDNA from males, since their
X-chromosome allele is active and unmethylated. A, Family Ro. Three X-chromosome alleles are identiﬁed in the grandparents of the propositus:
alleles 1 and 3 are from the grandmother, and allele 2 is deduced as originating from the deceased grandfather and is shared by his three
daughters (all females of generation II). The pattern of bands seen in the H lane for the females, even though not quantitative, is suggestive of
no preferential X inactivation of the two alleles. B, Family Fi. The grandmother is homozygous for the polymorphic repeat in exon 1 of the
AR gene, and analysis is therefore uninformative. However, the other two informative females show no preferential X inactivation of the two
alleles.
in the relative levels of serum iodothyronines offers the
possibility to investigate putative defects in thyroid hor-
mone transmembrane transport.
MCT8 was initially cloned during the physical char-
acterization of the region in Xq13.2 known to contain
the X-inactivation center (Lafreniere et al. 1994). The
deduced amino acid sequence and its hydrophobicity
predicted a protein with 12 TMDs and an N-terminal
domain rich in proline/glutamic acid repeats, compatible
with rapid conditional degradation of the protein. It was
found to be subject to inactivation, despite its location
within 600 kb from XIST, the gene that is expressed
exclusively from the inactive X. Cloning of the mouse
homologue showed 85% nucleotide identity with the
human gene and conservation of the overall protein
structure (Debrand et al. 1998). Recently, thyroid hor-
mone transport function was demonstrated in the rat
homologue of MCT8 by in vitro expression in Xenopus
oocytes (Friesema et al. 2003). It is characterized by a
10-fold increase in the uptake of a variety of iodothy-
ronines. Although a systematic survey of other potential
substrates was not undertaken, the four amino acids
tyrosine, tryptophan, phenylalanine, and leucine did not
compete with the transport of iodothyronines.
The severe neurological phenotype—despite mild per-
turbation of thyroid hormone levels, the lack of other
stigmata of generalized thyroid hormone deprivation,
and the lack of neurological improvement even after the
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normalization of serum TSH during treatment with thy-
roid hormone—suggested possible preferential function
in brain tissue. We therefore reexamined the expression
of MCT8 mRNA in different human tissues by real-time
PCR of RNA extracted from fresh tissues by TRIzol
reagent (Invitrogen). After reverse transcription with
random primers (Invitrogen), the cDNA template was
analyzed using two different primer pairs annealing to
coding sequences across exons 1 and 2 and exons 4 and
6 of MCT8. Signals at low cycles of 27 to 29 suggested
relative abundance of MCT8 mRNA in all tissues ex-
amined. Content relative to that in COS7 cells (29 cycles
p 1) was 0.5 brain, 3.1 thyroid, 2.3 adrenal, 2.7 liver,
1.1 placenta, and 1.0 pituitary. Results were corrected
for the abundance of 18S rRNA in the corresponding
samples.
We were also interested to explore the mechanism of
the apparent dominant expression of the thyroid but not
the neurological phenotype, as observed in the four fe-
male heterozygotes for the MCT8 mutations. Several
possibilities were considered, including a selective X in-
activation. For this purpose, we tested theX-inactivation
status using the androgen-receptor (AR) assay. The prim-
ers used ﬂank a sequence containing a highly polymor-
phic CAG repeat and two HhaI sites in exon 1 of the
AR gene (Allen et al. 1992). As previously shown, when
using the mock digested gDNA as the PCR template, all
alleles would get ampliﬁed, whereas using the HhaI-di-
gested gDNA as the template would amplify only the
inactive alleles, which are methylated and therefore re-
sistant to restriction digestion with HhaI. For gDNA
obtained from a male, digestion with HhaI should not
produce a PCR product. In a sample obtained from a
female, both alleles should be present if the X chro-
mosome is subject to random inactivation, or, in the case
of skewed inactivation, only the allele that is preferen-
tially inactivated will be ampliﬁed. Results from both
families are presented in ﬁgure 4 and show no clear
preferential X inactivation in informative females with
different AR alleles. These results are compatible with
both dominant-negative effect and haploinsufﬁciency as
mechanisms for the dominant expression of the thyroid
phenotype. This is not conclusive, since preferential X
inactivation may be tissue speciﬁc, and results obtained
in circulating mononuclear cells might not correlatewith
that in other tissues. No other tissues from the affected
females were available for testing.
The mechanism responsible for the observed pheno-
type remains unclear. The serum thyroid test abnor-
malities may represent differences in the rates of io-
dothyronine transport resulting from the reduction or
absence of MCT8. However, secondary effects on io-
dothyronine metabolism cannot be excluded. The dis-
crepancy between the thyroid and neurological ﬁndings
may be due to action of MCT8 in the brain that is
unrelated to thyroid hormone transport. This would not
be surprising, given its possible role in the transport of
other substrates. The occurrence of diabetes mellitus in
one of the affected males is probably not associated with
the MCT8 mutation.
Irrespective of the mechanism mediating the observed
defects, the ﬁnding of thyroid hormone abnormalities
linked to defects of MCT8 provides, for the ﬁrst time,
deﬁnite evidence that thyroid hormone transfer into cells
does not occur through passive diffusion. The physio-
logical role of other putative hormone transporters re-
mains to be determined.
Note added in proof.—We recently learned that the
laboratory of Professor Theo Visser has identiﬁedMCT8
mutations in members of two families with a phenotype
similar to that described in this work. Their results were
presented at the meeting of the American Thyroid As-
sociation, which took place in Palm Beach, FL, from
September 16 to September 22, 2003 (Thyroid 13:672).
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